Gene Therapy for Localized Scleroderma Gets Rare Pediatric Designation – Rare Disease Report
CNA Finance |
Gene Therapy for Localized Scleroderma Gets Rare Pediatric Designation
Rare Disease Report One month after receiving a Rare Pediatric Disease Designation for its gene therapy, FCX-007 to treat epidermolysis bullosa, the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation for FCX-013 to treat localized … Fibrocell's gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 … Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma FDA Designation A Boon For Fibrocell Science (FCSC) |
